Porous Antibody Separation Matrix for Short-Residence Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current separation matrices for continuous chromatography processes in therapeutic monoclonal antibody manufacturing are limited in achieving high dynamic binding capacities at very short residence times, particularly in shallow beds with low hydraulic resistance.
Innovation Solution
Development of a separation matrix with immobilized antibody-binding protein ligands on porous, spherical particles, such as crosslinked agarose, with specific Fc-binding domains and optimized ligand density and pore structure, allowing for high binding capacity and rapid mass transport.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional separation matrices are used in continuous chromatography processes, then the processes can be implemented, but high dynamic binding capacities at very short residence times cannot be achieved
Solution Approach 1:
The patent employs porous particles with optimized pore structures to enhance mass transport rates. The porous architecture provides high surface area for ligand immobilization while maintaining rapid antibody diffusion, enabling high dynamic binding capacity at short residence times. The pore size distribution is specifically optimized to balance adsorption capacity and mass transport kinetics.
Solution Approach 2:
The patent systematically optimizes multiple parameters including particle size (reducing to increase surface area), ligand density (increasing to enhance capacity), and pore structure (modifying to improve mass transport). These parameter changes collectively enable the matrix to achieve high dynamic binding capacity while maintaining very short residence times required for continuous chromatography.
2Productivity
If shallow beds with low hydraulic resistance are used, then flow rates can be increased, but binding capacity decreases with currently available matrices
Solution Approach 1:
The porous particle structure provides high internal surface area that compensates for the reduced bed depth. The optimized pore network ensures efficient mass transport even at high flow rates, maintaining high binding capacity in shallow beds with low hydraulic resistance.
Solution Approach 2:
The patent increases ligand density on the particle surface to compensate for the reduced bed volume in shallow columns. This higher surface density of binding sites maintains overall binding capacity while allowing operation at high flow rates through the low-resistance shallow bed configuration.
3Quantity of substance
If high ligand density is increased to improve binding capacity, then more antibodies can be bound, but mass transport rates may be affected
Solution Approach 1:
The porous particle structure with optimized pore size distribution allows high ligand density on the particle surface while maintaining open channels for rapid antibody diffusion. The pore architecture prevents mass transport limitations that would otherwise occur at high ligand densities by providing efficient diffusion pathways.
Solution Approach 2:
The patent creates a composite structure combining high-ligand-density surface layers with highly porous internal structures. This composite architecture simultaneously achieves high binding capacity through increased ligand density and maintains rapid mass transport through the optimized porous network, resolving the trade-off between these two parameters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables very short residence times with high binding capacity, suitable for continuous chromatography, maintaining efficiency and reducing operational costs.
Implementation Method 1
a) a feed is applied to a first chromatography column packed with a separation matrix comprising porous particles to which Fc-binding protein ligands have been covalently immobilized
Implementation Method 2
rapid mass transport
Implementation Method 3
mass transport
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A separation matrix comprising porous particles to which antibody-binding protein ligands have been covalently immobilized, wherein the density of said ligands is above 5 mg/ml, the volume-weighted median diameter of said porous particles is at least 10 and below 30 μm and the said porous particles have a gel phase distribution coefficient, expressed as KD for dextran of molecular weight 110 kDa, of 0.5-0.9.